SHUKRA MEDTECH LIMITED (SHUKRAMED) financials
SHUKRA MEDTECH LIMITED (SHUKRAMED) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap: ₹3,639Cr.
- Current Price: ₹82.2
- Stock P/E: 73.3
- ROE: 28.9%
- ROCE: 37.0%
- Book Value: ₹2.81
- Dividend Yield: 0.01%
- 52W High / Low: ₹84.8/26.3
In Sep 2026, SHUKRA MEDTECH LIMITED (SHUKRAMED) reported sales ₹44 Cr and net profit ₹16 Cr.
Annual TTM: sales ₹113 Cr, net profit ₹50 Cr.
Shareholding: Promoters 51.16% (Sep 2026), FIIs 0.43% (Sep 2026), DIIs 0.21% (Sep 2026), Public 48.20% (Sep 2026), No. of Shareholders 35,007% (Sep 2026).
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 11 | 13 | 5 | 6 | 39 | 6 | 24 | 44 |
| YoY Sales growth | -44% | +22% | +70% | +6% | +270% | -53% | +336% | +652% |
| Expenses | 7 | 6 | 4 | 6 | 12 | 6 | 2 | 22 |
| Operating Profit | 4 | 7 | 1 | -0 | 27 | 1 | 21 | 22 |
| OPM % | 37% | 55% | 24% | -7% | 69% | 11% | 90% | 50% |
| Other Income | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 8 | 1 | 0 | 27 | 0 | 20 | 21 |
| Tax % | 23% | 29% | 26% | -1,090% | 24% | 568% | 26% | 24% |
| Net Profit | 3 | 5 | 1 | 2 | 20 | -2 | 15 | 16 |
| EPS in Rs | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.34 | 0.36 |
| Raw PDF | — | — | — | — | — | — | — | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 12 | 11 | 20 | 59 | 75 | 33 | 57 | 113 |
| Sales growth | +109% | -6% | +83% | +187% | +27% | -56% | +74% | +222% |
| Expenses | 10 | 10 | 18 | 53 | 55 | 20 | 28 | 42 |
| Operating Profit | 2 | 1 | 3 | 5 | 19 | 13 | 29 | 71 |
| OPM % | 13% | 13% | 14% | 9% | 26% | 39% | 51% | 63% |
| Other Income | 0 | 0 | 0 | 1 | 3 | 4 | 5 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 |
| Profit before tax | 0 | 0 | 1 | 4 | 20 | 13 | 29 | 69 |
| Tax % | 82% | -90% | 26% | 1% | 7% | 28% | 23% | — |
| Net Profit | 0 | 0 | 1 | 4 | 19 | 10 | 22 | 50 |
| EPS in Rs | 0.00 | 0.01 | 0.02 | 0.15 | 0.42 | 0.22 | 0.50 | 1.12 |
| Dividend Payout % | 0% | 0% | 10% | 4% | 6% | 5% | 2% | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 4 | 11 | 44 | 44 | 44 |
| Reserves | 14 | 14 | 15 | 21 | 47 | 19 | 46 | 80 |
| Borrowings | 8 | 10 | 3 | 5 | 3 | 4 | 5 | 21 |
| Other Liabilities | 10 | 10 | 15 | 45 | 17 | 20 | 23 | 33 |
| Total Liabilities | 34 | 36 | 35 | 75 | 78 | 87 | 117 | 178 |
| Fixed Assets | 17 | 18 | 18 | 20 | 20 | 19 | 22 | 21 |
| CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 12 | 26 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 14 | 16 | 16 | 53 | 56 | 65 | 84 | 131 |
| Total Assets | 34 | 36 | 35 | 75 | 78 | 87 | 117 | 178 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 1 | 1 | 8 | 3 | -5 | 8 | 3 |
| Cash from Investing Activity | -2 | -3 | -2 | -2 | -4 | -1 | -1 | -14 |
| Cash from Financing Activity | 2 | 2 | 2 | -7 | 5 | 12 | -5 | 5 |
| Net Cash Flow | 0 | -0 | 0 | -0 | 4 | 6 | 2 | -6 |
| Free Cash Flow | -2 | -2 | -1 | 6 | -1 | -7 | 5 | -13 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 25% | 81% | 38% | 292% | 64% | -24% | 92% | 17% |
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 51.16% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.43% |
| DIIs | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.21% |
| Public | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.92% | 48.93% | 48.20% |
| No. of Shareholders | 17,844 | 18,231 | 20,337 | 21,441 | 25,649 | 27,173 | 28,384 | 35,007 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 345 | 245 | 318 | 132 | 187 | 120 | 98 | 148 |
| Inventory Days | 100 | 169 | 221 | 139 | 25 | 19 | 447 | 320 |
| Days Payable | 1,161 | 786 | 702 | 303 | 271 | 59 | 414 | 232 |
| Cash Conversion Cycle | -717 | -372 | -163 | -32 | -58 | 80 | 131 | 236 |
| Working Capital Days | 440 | 226 | 278 | 57 | 41 | 157 | 403 | 352 |
| ROCE % | 4% | 0% | 1% | 6% | 19% | 44% | 22% | 37% |
Shukra Medtech Limited
₹3,639Cr.
₹82.2
₹84.8/26.3
73.3
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
Quarterly results
Profit & loss
Shareholding trend
Balance sheet
Cash flows
Key ratios
Frequently asked questions
What is the market cap of SHUKRA MEDTECH LIMITED (SHUKRAMED)?
The reported market capitalisation for SHUKRA MEDTECH LIMITED (SHUKRAMED) is ₹3,639Cr. on Fincrux. Figures may update with market data and filings.
What is the current share price of SHUKRAMED?
The current price shown for SHUKRA MEDTECH LIMITED (SHUKRAMED) on Fincrux is ₹82.2 with a 52-week high/low of ₹84.8/26.3.
What is the P/E ratio of SHUKRA MEDTECH LIMITED (SHUKRAMED)?
The stock P/E for SHUKRA MEDTECH LIMITED (SHUKRAMED) is 73.3 on Fincrux, with ROE at 28.9% and ROCE at 37.0%.
What were SHUKRAMED latest quarterly results?
For Sep 2026, SHUKRA MEDTECH LIMITED (SHUKRAMED) reported sales ₹44 Cr and net profit ₹16 Cr (figures in ₹ crore unless noted).
What are SHUKRAMED annual sales and net profit?
For TTM, SHUKRA MEDTECH LIMITED (SHUKRAMED) shows sales of ₹113 Cr and net profit of ₹50 Cr on the Fincrux profit & loss statement.
Who owns SHUKRA MEDTECH LIMITED (SHUKRAMED)?
Latest shareholding for SHUKRA MEDTECH LIMITED (SHUKRAMED) on Fincrux: Promoters 51.16% (Sep 2026), FIIs 0.43% (Sep 2026), DIIs 0.21% (Sep 2026), Public 48.20% (Sep 2026), No. of Shareholders 35,007% (Sep 2026).
Where can I find SHUKRA MEDTECH LIMITED (SHUKRAMED) financials?
SHUKRA MEDTECH LIMITED (SHUKRAMED) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.
Does Fincrux show SHUKRAMED balance sheet and cash flow?
Yes. The SHUKRA MEDTECH LIMITED (SHUKRAMED) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.